

IN THE CLAIMS:

Please cancel claim 36 and add new claim 40.

Please amend claims 37-39 as set forth below. For the Examiner's convenience, all of the pending claims are provided hereinbelow.

C¹
36. (canceled) A method of inhibiting the pathological proliferation of ovarian cancer cells in a patient, the method comprising inhibiting PI kinase activity in the cells.

37. (amended) A method of inhibiting the pathological proliferation of ovarian cancer cells in a patient, the method comprising [The method of claim 36, wherein the PIK3CA activity is inhibited by] administering a therapeutically effective dose of an inhibitor of PI kinase to the patient.

38. (amended) The method of claim [37] 36, wherein the inhibitor of PI kinase is a non-peptidic inhibitor of enzyme activity.

[40] 39. (amended) The method of claim 38, wherein the non-peptidic inhibitor is LY294002.

C²
40. (new) A method of identifying a compound that inhibits the activity of PIK3CA in an ovarian cancer cell that overexpresses PIK3CA, the method comprising:
contacting the ovarian cancer cell with a compound that inhibits PI kinase; and
detecting a decrease in PI kinase activity in the ovarian cancer cell.

REMARKS

With entry of the present amendment, claims 37-40 are pending in the application. The Examiner's rejections are addressed in the order presented in the Office Action mailed June 16, 2000.